Larimar Therapeutics, Inc. (LRMR)

Larimar Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	33.22	26.75	26.83	70.1	68.15
Short-Term Investments	150.24	60.04	91.6	-	24.49
Cash & Short-Term Investments	183.45	86.79	118.43	70.1	92.64
Cash Growth	111.38%	-26.71%	68.95%	-24.33%	9081.17%
Other Receivables	1.05	0.33	-	0.21	0.03
Receivables	1.05	0.33	-	0.21	0.03
Prepaid Expenses	10.8	3.05	2.31	1.9	5.28
Total Current Assets	195.3	90.18	120.74	72.2	97.95
Property, Plant & Equipment	3.72	3.76	3.69	4.46	4.98
Other Long-Term Assets	1.2	2	1.98	2.01	1.76
Total Assets	200.23	95.94	126.41	78.67	104.69
Accounts Payable	2.42	1.28	1.69	1.66	2.63
Accrued Expenses	20.87	7.39	8.41	6.59	5.84
Current Portion of Leases	1.06	0.84	0.61	0.59	0.52
Total Current Liabilities	24.36	9.51	10.71	8.85	8.99
Long-Term Leases	4.06	4.71	4.8	5.41	6
Total Liabilities	28.41	14.22	15.5	14.25	14.99
Common Stock	0.06	0.04	0.04	0.02	0.02
Additional Paid-In Capital	440.76	270.15	262.5	180.65	155.29
Retained Earnings	-269.16	-188.55	-151.61	-116.25	-65.61
Comprehensive Income & Other	0.15	0.08	-0.03	-	0
Shareholders' Equity	171.81	81.72	110.9	64.41	89.69
Total Liabilities & Equity	200.23	95.94	126.41	78.67	104.69
Total Debt	5.12	5.55	5.41	6	6.52
Net Cash (Debt)	178.34	81.24	113.02	64.1	86.12
Net Cash Growth	119.51%	-28.12%	76.33%	-25.58%	9343.09%
Net Cash Per Share	2.91	1.85	4.39	3.73	7.25
Filing Date Shares Outstanding	64.03	63.8	43.27	17.71	15.37
Total Common Shares Outstanding	63.82	43.91	43.27	17.71	15.37
Working Capital	170.95	80.67	110.03	63.36	88.96
Book Value Per Share	2.69	1.86	2.56	3.64	5.84
Tangible Book Value	171.81	81.72	110.9	64.41	89.69
Tangible Book Value Per Share	2.69	1.86	2.56	3.64	5.84
Machinery	2.38	1.86	1.71	1.61	1.38
Leasehold Improvements	0.05	0.05	0.03	0.03	-

Updated Mar 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q